ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2026
Amivantamab Plus Lazertinib in Atypical
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Profiling EGFR, c-MET, and B7H3 co-expression to guide next-generation dual-drug conjugate strategies in colorectal cancer.The journal of pathology. Clinical research · 2026Article
- Article
- Strengthening the EGFR blockade for those lung cancers that need it most.Translational lung cancer research · 2026Article
- Prevalence and Clinical Implications of Somatic and Germline EGFR Mutations in Patients with Non-Small-Cell Lung Cancer.Cancers · 2026Review
- Beyond exon 19 and 21: positioning lazertinib and the next generation of strategies for uncommonJournal of thoracic disease · 2026Article
- Resistance to EGFR Inhibitors in NSCLC: Mechanistic Insights and Emerging Therapies.International journal of molecular sciences · 2026Review
- Are lazertinib and osimertinib comparable for treating advancedJournal of thoracic disease · 2026Article
- The COCOON trial: wrapping potent EGFR therapy in proactive supportive care.Journal of thoracic disease · 2026Article
- Lung cancer withTranslational lung cancer research · 2026Review
- Targeting heterogeneity in atypical epidermal growth factor receptor-mutated non-small cell lung cancer: insights from CHRYSALIS-2.Translational lung cancer research · 2026Article
- Prolonged complete metabolic response to chemotherapy combined with amivantamab with high grade cutaneous toxicity after osimertinib resistance in an uncommonTranslational lung cancer research · 2026Article
- Targeting the Uncommon: A Case Report of Osimertinib Response in Advanced NSCLC Patient with Dual EGFR (E701fs and L702fs) Frameshift Deletions.Current oncology (Toronto, Ont.) · 2026Article
- Case Report: Dramatic response to amivantamab plus chemotherapy in EGFR G719A-mutant lung adenocarcinoma with liver and peritoneal metastases.Frontiers in oncology · 2026Article
- Research progress and challenges in the treatment of oncogene-addicted non-small cell lung cancer.Cancer biology & medicine · 2025Review
- Article
- Unveiling the Synergistic Potential: Bispecific Antibodies in Conjunction with Chemotherapy for Advanced Non-Small-Cell Lung Cancer Treatment.Current oncology (Toronto, Ont.) · 2025Review
- Recent advances in therapeutic strategies for non-small cell lung cancer.Journal of hematology & oncology · 2025Review
- The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC.Cell reports. Medicine · 2025Article
- How to select between osimertinib or afatinib in P-loop and αC-helix compressing (G719X, S768I) or classical-like (L861Q) EGFR mutations: what preclinical models and clinical data have taught us in the early 2020s.Translational cancer research · 2025Article
- Navigating restriction from interstitial lung disease (ILD) with stereotactic ablative radiotherapy (SABR) in early-stage non-small cell lung cancer: soaring beyond the current treatment paradigm.Translational cancer research · 2025Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
33 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeFor patients with advanced non-small cell lung cancer (NSCLC) harboring atypical epidermal growth factor receptor ( PATIENTS AND
methodsCHRYSALIS-2 Cohort C enrolled participants with NSCLC harboring atypical
resultsAs of January 12, 2024, 105 participants received amivantamab-lazertinib. Most common atypical mutations were G719X (56%), L861X (26%), and S768I (23%), including single and compound mutations. In the overall population (median follow-up: 16.1 months), the ORR was 52% (95% CI, 42 to 62). The median duration of response (mDoR) was 14.1 months (95% CI, 9.5 to 26.2). The median progression-free survival (mPFS) was 11.1 months (95% CI, 7.8 to 17.8); median overall survival (mOS) was not estimable (NE; 95% CI, 22.8 to NE). Adverse events were consistent with previous studies and primarily grade 1 and 2. Among treatment-naïve participants, the ORR was 57% (95% CI, 42 to 71). The mPFS was 19.5 months (95% CI, 11.2 to NE), the mDoR was 20.7 months (95% CI, 9.9 to NE), and mOS was NE (95% CI, 26.3 to NE). Solitary or compound
conclusionIn participants with atypical
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.